Head to head
Exenatide against Liraglutide
Two of the earliest GLP-1 agonists, compared directly in a trial that failed to show non-inferiority in the direction its sponsor was testing. Both are older than the drugs that displaced them, and both are still prescribed.
Column A
ExenatideExenatide (GLP-1 receptor agonist)
The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.
Column B
LiraglutideLiraglutide (GLP-1 receptor agonist)
A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
These two were tested against each other directly
A head to head trial, not two separate records compared by us.
HbA1c fell 1.48 percent on liraglutide against 1.28 percent on exenatide once weekly, a treatment difference of 0.21 percentage points (95% CI 0.08 to 0.33) which did not meet the predefined non-inferiority criterion. Nausea occurred in 21 percent on liraglutide against 9 percent on exenatide, diarrhoea in 13 against 6 percent and vomiting in 11 against 4 percent. Discontinuation for adverse events was 5 percent against 3 percent.
What the trial was
26 week, open-label, randomised, parallel-group study at 105 sites in 19 countries. 912 adults with type 2 diabetes on lifestyle modification and oral antihyperglycaemic drugs were randomised 1:1 to once-weekly exenatide 2 mg or once-daily liraglutide 1.8 mg. Participants and investigators were not masked. Primary endpoint was change in HbA1c at week 26, analysed by intention to treat.
What the authors concluded
The authors conclude that both drugs improved glycaemic control with greater reductions on liraglutide, and that this together with the differences in injection frequency and tolerability could inform treatment decisions.
Where this result is weak
Open-label, 26 weeks, and an HbA1c endpoint rather than any event a patient would notice. It was funded by Eli Lilly and Amylin Pharmaceuticals, who made the arm that did not win, which is an unusual direction for a sponsorship bias. It tested exenatide in its weekly formulation only, and it enrolled people with type 2 diabetes, so it says nothing about weight loss use in people without diabetes.
Side by side, on the facts we can check
| Attribute | Exenatide | Liraglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Byetta, Bydureon) | FDA-approved (Victoza for T2D; Saxenda for weight management) |
| Half-life | ~2.4 hours (immediate release) | ~13 hours |
| Molecular weight | 4,186.6 Da | 3,751.2 Da |
| Mechanism | Agonizes the GLP-1 receptor with roughly 53% homology to human GLP-1, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying. | Activates the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. |
| Human studies cited | 2 | 2 |
| Legal status, US | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Exenatide and Liraglutide?
Exenatide: The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class. Liraglutide: A once-daily GLP-1 receptor agonist and the first GLP-1 approved specifically for obesity, with proven cardiovascular benefit.
Which has stronger research evidence, Exenatide or Liraglutide?
This database does not grade compounds. It counts what was run in people: 2 of the 3 studies cited on the Exenatide profile were human work, against 2 of 2 for Liraglutide. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Exenatide and Liraglutide FDA-approved?
Exenatide: FDA-approved (Byetta, Bydureon). Liraglutide: FDA-approved (Victoza for T2D; Saxenda for weight management).
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.